Pipeline

How About a Moon Shot for Orphan Diseases?

How About a Moon Shot for Orphan Diseases?

You can see it everywhere: on TV and in newspapers and ads. The decades of struggle against cancer are paying off.

Drugmakers revive R&D focus on long stagnant women's health market

Drugmakers revive R&D focus on long stagnant women's health market

By

Fueled by innovation in new treatments, the underserved women's health market has begun to turn the proverbial corner. What took it so long?

Long neglected, the osteoporosis market prepares for new entrants

Long neglected, the osteoporosis market prepares for new entrants

By

The osteoporosis drug market is bracing for the advent of potentially game-changing treatments.

Bolstered by new data, Radius Health focuses on unmet needs in the osteoporosis market

Bolstered by new data, Radius Health focuses on unmet needs in the osteoporosis market

By

Only one new osteoporosis drug has been approved over the last six years.

Opdivo bet backfires, creates opening for Merck to pursue DTC

Opdivo bet backfires, creates opening for Merck to pursue DTC

By

A massive disappointment for Bristol-Myers Squibb's Opdivo in first-line lung cancer has leveled the playfield for Merck's Keytruda.

Five things for pharma marketers to know: Friday, August 5, 2016

Five things for pharma marketers to know: Friday, August 5, 2016

By

Opdivo fails to meet endpoint in new lung cancer patients; abuse-deterrent drug gets nod from FDA panel; Cephalon settles pay-for-delay case

As immuno-oncology therapies evolve, so will the marketing

As immuno-oncology therapies evolve, so will the marketing

By

Interest in oncology is on the rise as the blockbuster drug era breathes its last, and this has altered marketing in cancer care.

Top 25 oncology products in 2015

Top 25 oncology products in 2015

Despite the arrivals of new drugs, Genentech continues to be the market leader. Its drugs, Rituxan, Avastin, and Herceptin, are the category leaders, generating a total of $9.29 billion in sales.

CAR-T therapies: the future of cancer care, or an industry pipe dream?

CAR-T therapies: the future of cancer care, or an industry pipe dream?

By

While analysts predict a first-in-class appearance before the FDA by 2018, many obstacles have arisen.

Five things for pharma marketers to know: Friday, July 22, 2016

Five things for pharma marketers to know: Friday, July 22, 2016

By

Herceptin biosimilar meets endpoint in clinical trial; Roche plans to launch five new drugs over the next year; government seeks to block insurer deals

Five things for pharma marketers to know: Monday, July 18, 2016

Five things for pharma marketers to know: Monday, July 18, 2016

By

Roche's blood cancer drug fails to meet trial goal; the FDA says Valeant's psoriasis drug carries risk of suicide; Facebook tests disappearing messages

Five things for pharma marketers to know: Wednesday, June 29, 2016

Five things for pharma marketers to know: Wednesday, June 29, 2016

By

GIlead Sciences' new HCV treatment receives approval; FDA adcomm votes in favor of Jardiance health-outcomes' claims; FDA names head of new oncology center

Five things for pharma marketers to know: Tuesday, June 28, 2016

Five things for pharma marketers to know: Tuesday, June 28, 2016

By

Opdivo nets sixth Breakthrough Therapy designation; AstraZeneca seeks rare indication to block Crestor generics; Endo mulls sale to reduce debt

New first-line lung data is positive for Merck's Keytruda, but competitor looms large

New first-line lung data is positive for Merck's Keytruda, but competitor looms large

By

A trial studying Keytruda met its endpoint in first-line lung cancer patients.

Five things for pharma marketers to know: Monday, June 13, 2016

Five things for pharma marketers to know: Monday, June 13, 2016

By By

A new Sanofi combination diabetes drug meets clinical trial targets; IBM partners with the American Diabetes Association; Dr. Reddy's to buy eight Teva drugs

Bristol-Myers Squibb's Yervoy, Opdivo combo data confers edge in lung cancer

Bristol-Myers Squibb's Yervoy, Opdivo combo data confers edge in lung cancer

By

Investors said a combination of Opdivo and Yervoy is the top-performing regimen in a niche of non-small cell lung-cancer patients.

ASCO 2016 Preview: Expect data on CDK inhibitors, CAR-T therapies, and pricing

ASCO 2016 Preview: Expect data on CDK inhibitors, CAR-T therapies, and pricing

By

Competition among new breast cancer drugs, an immunotherapy contender, and pricing discussions headline one of the biggest cancer conferences of the year.

Merck educates doctors about biosimilars, long before it will sell one in the U.S.

Merck educates doctors about biosimilars, long before it will sell one in the U.S.

By

Drugmakers like Merck are making a big education push as they lay the groundwork for future biosimilars.

Drugmakers renew interest in antibiotic development

Drugmakers renew interest in antibiotic development

By

The goal is to develop medications that move beyond the high-toxicity and low-efficacy profiles of older drugs.

Five things for pharma marketers to know: Wednesday, May 18, 2016

Five things for pharma marketers to know: Wednesday, May 18, 2016

By

Opdivo nets new indication; government to view Humira patent; AstraZeneca's asthma drug expected to be filed this year

With competition lurking, Eli Lilly's baricitinib must show unparalled efficacy

With competition lurking, Eli Lilly's baricitinib must show unparalled efficacy

By

The bar for market success has been set high for baricitinib.

Five things for pharma marketers to know: Tuesday, May 3, 2016

Five things for pharma marketers to know: Tuesday, May 3, 2016

By

IMS and Quintiles to merge and create $17 billion firm; Biogen spins off hemophilia company; Google partners with the National Health Service

Five things for pharma marketers to know: Friday, April 22, 2016

Five things for pharma marketers to know: Friday, April 22, 2016

By

AstraZeneca to sequence two million genomes; Valeant considering Perrigo CEO as its new chief executive; AMA and PhRMA each spent $6 million on lobbying

Five things for pharma marketers to know: Wednesday, April 20, 2016

Five things for pharma marketers to know: Wednesday, April 20, 2016

By

Immuno-oncology drugs showing results in hard-to-treat cancers; Express Scripts responds to Anthem lawsuit; BI and Lilly plan outcomes trials for Jardiance

Five things for pharma marketers to know: Wednesday, March 30, 2016

Five things for pharma marketers to know: Wednesday, March 30, 2016

By

There are 23 biosimilars ready to file with the FDA; an FDA committee votes in favor of Parkinson's disease drug; Bloomberg funds new immunotherapy center

Drugmakers move to counteract expiring patents with new respiratory drugs

Drugmakers move to counteract expiring patents with new respiratory drugs

By

Symptom-driven care is falling out of fa­vor with lung-drug leaders increasingly interested in assigning optimal treatment approaches to patient conditions.

Corbus bets on cystic-fibrosis market with Resunab

Corbus bets on cystic-fibrosis market with Resunab

By

Current treatments, including steroids and ibuprofen, help control symptoms. But the side-effect profiles are difficult for patients to manage.

Five things for pharma marketers to know: Monday, March 7, 2016

Five things for pharma marketers to know: Monday, March 7, 2016

By

European regulators launch speedier drug approval process: AbbVie and Boehringer Ingelheim to partner on psoriasis drug; the FDA approves hemophilia B drug

Five things for pharma marketers to know: Friday, February 26, 2016

Five things for pharma marketers to know: Friday, February 26, 2016

By

Bristol-Myers Squibb considered immunotherapy market leader; McKesson buys two cancer-care companies; Bayer names new CEO

With support of FDA committee, Remicade biosimilar edges closer to market

With support of FDA committee, Remicade biosimilar edges closer to market

By

The FDA is set to announce its decision on the drug in April.

OPINION

Email Newsletters